Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2015 2
2016 2
2017 1
2018 2
2019 1
2021 1
2023 0

Text availability

Article attribute

Article type

Publication date

Search Results

7 results

Results by year

Citations

1 article found by citation matching

Search results

Filters applied: . Clear all
Page 1
Assessment of Use of Combined Dextromethorphan and Quinidine in Patients With Dementia or Parkinson Disease After US Food and Drug Administration Approval for Pseudobulbar Affect.
Fralick M, Sacks CA, Kesselheim AS. Fralick M, et al. JAMA Intern Med. 2019 Feb 1;179(2):224-230. doi: 10.1001/jamainternmed.2018.6112. JAMA Intern Med. 2019. PMID: 30615021 Free PMC article.
IMPORTANCE: In 2010, the US Food and Drug Administration (FDA) approved a combination of dextromethorphan hydrobromide and quinidine sulfate for the treatment of pseudobulbar affect after studies in patients …
IMPORTANCE: In 2010, the US Food and Drug Administration (FDA) approved a combination of dextro …
PRISM II: an open-label study to assess effectiveness of dextromethorphan/quinidine for pseudobulbar affect in patients with dementia, stroke or traumatic brain injury.
Hammond FM, Alexander DN, Cutler AJ, D'Amico S, Doody RS, Sauve W, Zorowitz RD, Davis CS, Shin P, Ledon F, Yonan C, Formella AE, Siffert J. Hammond FM, et al. BMC Neurol. 2016 Jun 9;16:89. doi: 10.1186/s12883-016-0609-0. BMC Neurol. 2016. PMID: 27276999 Free PMC article. Clinical Trial.
BACKGROUND: Phase 3 trials supporting dextromethorphan/quinidine (DM/Q) use as a treatment for pseudobulbar affect (PBA) were conducted in patients with amyotrophic lateral sclerosis (ALS) or multiple sclerosis (MS). ...Secondary outcomes includ …
BACKGROUND: Phase 3 trials supporting dextromethorphan/quinidine (DM/Q) use as a treatment for pseudobulbar affect …
Effect of Dextromethorphan-Quinidine on Agitation in Patients With Alzheimer Disease Dementia: A Randomized Clinical Trial.
Cummings JL, Lyketsos CG, Peskind ER, Porsteinsson AP, Mintzer JE, Scharre DW, De La Gandara JE, Agronin M, Davis CS, Nguyen U, Shin P, Tariot PN, Siffert J. Cummings JL, et al. JAMA. 2015 Sep 22-29;314(12):1242-54. doi: 10.1001/jama.2015.10214. JAMA. 2015. PMID: 26393847 Clinical Trial.
OBJECTIVE: To assess the efficacy, safety, and tolerability of dextromethorphan hydrobromide-quinidine sulfate for Alzheimer disease-related agitation. ...CONCLUSIONS AND RELEVANCE: In this preliminary 10-week phase 2 randomized clinical trial of pa …
OBJECTIVE: To assess the efficacy, safety, and tolerability of dextromethorphan hydrobromide-quinidine sulfate for Alzh …
Identification of pseudobulbar affect symptoms in the nursing home setting: Development and assessment of a screening tool.
Allen C, Zarowitz B, O'Shea T, Peterson E, Yonan C, Waterman F. Allen C, et al. Geriatr Nurs. 2018 Jan-Feb;39(1):54-59. doi: 10.1016/j.gerinurse.2017.06.002. Epub 2017 Aug 12. Geriatr Nurs. 2018. PMID: 28807457
Pseudobulbar Affect (PBA) is a neurologic condition characterized by involuntary outbursts of crying and/or laughing disproportionate to patient mood or social context. ...Using a multivariable regression and best decision rule analysis, we found PBA in nursi …
Pseudobulbar Affect (PBA) is a neurologic condition characterized by involuntary outbursts of crying and/or laughing dispropor …
Prediction of Cardiovascular Risk to Guide Primary Prevention.
Curfman GD. Curfman GD. JAMA Intern Med. 2018 Sep 1;178(9):1240-1241. doi: 10.1001/jamainternmed.2018.3131. JAMA Intern Med. 2018. PMID: 30039158 Free PMC article.
IMPORTANCE: In 2010, the US Food and Drug Administration approved a combination of dextromethorphan hydrobromide and quinidine sulfate with an Orphan Drug Act designation for the treatment of pseudobulbar af …
IMPORTANCE: In 2010, the US Food and Drug Administration approved a combination of dextromethor …
An open-label study to assess safety, tolerability, and effectiveness of dextromethorphan/quinidine for pseudobulbar affect in dementia: PRISM II results.
Doody RS, D'Amico S, Cutler AJ, Davis CS, Shin P, Ledon F, Yonan C, Siffert J. Doody RS, et al. CNS Spectr. 2016 Dec;21(6):450-459. doi: 10.1017/S1092852915000620. Epub 2015 Oct 16. CNS Spectr. 2016. PMID: 26471212
BACKGROUND: Dextromethorphan (DM)/quinidine (Q) is an approved treatment for pseudobulbar affect (PBA) based on trials in amyotrophic lateral sclerosis or multiple sclerosis. ...Adverse events included headache (7.5%), urinary tract infection (4 …
BACKGROUND: Dextromethorphan (DM)/quinidine (Q) is an approved treatment for pseudobulbar affect (PBA) ba …
Safety of Memantine in Combination with Potentially Interactive Drugs in the Real World: A Pharmacovigilance Study Using the Japanese Adverse Drug Event Report (JADER) Database.
Sato K, Mano T, Iwata A, Toda T. Sato K, et al. J Alzheimers Dis. 2021;82(3):1333-1344. doi: 10.3233/JAD-210524. J Alzheimers Dis. 2021. PMID: 34151816 Free PMC article.
Drug-drug interactions between memantine and these drugs were assessed using multiplicative and additive models. ...CONCLUSION: The real-world JADER data did not raise the concern about the interactive increase in the neuropsychiatric AEs in patients w …
Drug-drug interactions between memantine and these drugs were assessed using multiplicative and additive models. ...CON …